Greg Verdine is a venture partner on a16z’s Bio + Health team and a scientist and entrepreneur developing new drug modalities. He cofounded and leads LifeMine Therapeutics and is an emeritus professor at Harvard. He co-founded FogPharma, now Parabilis Medicines, served as its CEO from 2015 to 2023, and is its vice chair and CEO emeritus. His research helped establish approaches to drug targets previously considered undruggable.
Greg Verdine is a venture partner on a16z’s Bio + Health team and a scientist and entrepreneur developing new drug modalities. He cofounded and leads LifeMine Therapeutics and is an emeritus professor at Harvard. He co-founded FogPharma, now Parabilis Medicines, served as its CEO from 2015 to 2023, and is its vice chair and CEO emeritus. His research helped establish approaches to drug targets previously considered undruggable.
Career
Greg Verdine studied at Columbia University (Ph.D. in Chemistry), Saint Joseph’s University (B.S. in Chemistry), and Massachusetts Institute of Technology and Harvard Medical School (NIH postdoctoral fellowship in molecular biology).
Venture Partner, Bio + Health at Andreessen Horowitz (a16z) from 2023-04 to Present
Venture Partner at Third Rock Ventures from 2008-01 to 2015-12
Venture Partner at TPG Biotech from 2007 to 2008